Clinical trial
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With…
NCT00093353 · Children's Hospital Los Angeles, Other · Completed
Key facts
| NCT number | NCT00093353 |
|---|---|
| Title | N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma |
| Official title | A Phase I Study Of Oral Irinotecan, Temozolomide, Cefixime In Children With Recurrent/Resistant High-Risk Neuroblastoma |
| Lead sponsor | Children's Hospital Los Angeles, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma |
| Intervention type | Drug |
| Interventions | cefixime, irinotecan hydrochloride, temozolomide |
| Enrollment | 30 |
| Start date | May 1, 2004 |
| Primary completion | Jul 1, 2006 |
| First posted | Oct 8, 2004 |
| Last update posted | Oct 15, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: